Total buying$00 buys
IAM
Iambic Therapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$00 sells
Net open-market+$0Buying minus selling
Active insiders11Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 16, 2026
Open-market transaction mix · 0 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 0 | 16 | $0 | $0 | $0 |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (11)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- EV+$0
- VJ+$0
- TM+$0
- SS+$0
- RH+$0
IAM transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
IAMIambic Therapeutics, Inc. | Emster Kurt VonDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Vogelstein R JacobDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Tagliaferri MaryDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Sharp ShaliniDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Rastetter William HDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Rachlin Evan LockwoodDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Secora MichaelCFO · CCDO | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Secora MichaelCFO · CCDO | A · grantSEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Olson Peter ACSO | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Olson Peter ACSO | A · grantSEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Josephson NeilCMO | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Josephson NeilCMO | A · grantSEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Manby Frederick RCTO | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Manby Frederick RCTO | A · grantSEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Miller Thomas F.CEO | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
IAMIambic Therapeutics, Inc. | Miller Thomas F.CEO | A · grantSEC filing ↗ | $0View disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period16transactionstxns
- A · Grants / awards · dominant16 · 100%
Activity by reported role
A joint filing can contribute to multiple rolesDirector6
CCDO2
Chief executive officer2
Chief financial officer2
CMO2
CSO2
CTO2
Reported Holdings After
Separated by insider, security, and ownership type
Miller Thomas F.Common Stock · Direct
1,410,756Oct 14, 2026
Miller Thomas F.Employee Stock Option (right to buy) · Direct
793,200Oct 14, 2026
Manby Frederick RCommon Stock · Direct
1,862,665Oct 14, 2026
Manby Frederick REmployee Stock Option (right to buy) · Direct
793,200Oct 14, 2026
Josephson NeilCommon Stock · Direct
71,459Oct 14, 2026
Josephson NeilEmployee Stock Option (right to buy) · Direct
185,900Oct 14, 2026
Olson Peter ACommon Stock · Direct
30,909Oct 14, 2026
Olson Peter AEmployee Stock Option (right to buy) · Direct
116,900Oct 14, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Iambic Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Iambic Therapeutics, Inc.?
EMSTER KURT VON, Vogelstein R Jacob, TAGLIAFERRI MARY, Sharp Shalini, RASTETTER WILLIAM H, Rachlin Evan Lockwood, Secora Michael, Olson Peter A, Josephson Neil, Manby Frederick R, Miller Thomas F..
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.